FDA Approves Regeneron's EYLEA HD for Macular Edema Following Retinal Vein Occlusion

Reuters02-02 20:04
FDA Approves Regeneron's EYLEA HD for Macular Edema Following Retinal Vein Occlusion

Regeneron Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO). The approval is based on data from the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks. EYLEA HD provides the first every-two-month treatment option for these patients, who previously required more frequent treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment